Picture of Basilea Pharmaceutica AG, Allschwil logo

BSLN — Basilea Pharmaceutica AG, Allschwil News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Basilea Announces Agreement With Innoviva Specialty Therapeutics For Commercialization Of Zevtera In The United States

Dec 16 (Reuters) - Basilea Pharmaceutica AG Allschwil
 BSLN.S :
    * BASILEA ANNOUNCES AGREEMENT WITH INNOVIVA SPECIALTY
THERAPEUTICS
FOR THE COMMERCIALIZATION OF ANTIBIOTIC ZEVTERA® (CEFTOBIPROLE)
IN THE UNITED STATES
    * BASILEA PHARMACEUTICA AG ALLSCHWIL - TO RECEIVE $4 MILLION
UPFRONT PAYMENT, UP TO $223 MILLION IN MILESTONES

Source text:  ID:nGNXRFJGH 
Further company coverage:  BSLN.S 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Basilea Pharmaceutica AG, Allschwil

See all news